Reported Earlier, Tiziana Life Sciences Secures $5M in Direct Offering Of 5.3M Shares At $0.95/ Share for Immunotherapy Development
Portfolio Pulse from Benzinga Newsdesk
Tiziana Life Sciences has secured $5 million through a direct offering of 5.3 million shares at $0.95 each. The funds will support clinical trials and development of their lead candidate, foralumab, for various medical conditions.
October 31, 2024 | 8:12 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tiziana Life Sciences has raised $5 million through a direct offering, selling 5.3 million shares at $0.95 each. The funds will be used for clinical trials and development of foralumab, their lead candidate, for multiple sclerosis and Alzheimer's.
The direct offering provides Tiziana with necessary funds to advance its clinical trials, which is a positive development for the company. The ability to raise capital and invest in promising therapies can lead to future growth and potential breakthroughs, positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100